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Abstract
Background:  The 17-item Hamilton Depression Rating Scale (HAM-D17) remains the 'gold
standard' for measuring treatment outcomes in clinical trials of depressed patients. The
Montgomery sberg Depression Rating Scale (MADRS), Clinical Global Impressions-Severity (CGI-
S) and -Improvement (CGI-I) scales are also widely used.
Objective:  This analysis of data from 22 double-blind, placebo-controlled clinical studies of
venlafaxine in adult patients with major depressive disorder was aimed at assessing correlations
among these 4 scales.
Methods: Changes from baseline for MADRS, HAM-D17 and CGI-S, and end point CGI-I scores
and response (≥50% decrease from baseline HAM-D17 or MADRS, or CGI-S or CGI-I score ≤2)
were analysed. Pearson correlation coefficients were calculated for all pairs of the four scales
(HAM-D17/MADRS, HAM-D17/CGI-S, HAM-D17/CGI-I, MADRS/CGI-S, MADRS/CGI-I, CGI-S/
CGI-I) at different time points. Effect sizes were calculated using the Cohen d.
Results: Correlations were significant at all time points (p < 0.0001), increased over the course of
treatment, and were similar across treatment groups. Effect sizes ranged from 0.31 to 0.42; MADRS
and CGI-I effect sizes were slightly greater compared with HAM-D17 or CGI-S for continuous
measures and response.
Conclusion: Although MADRS and CGI-I were more sensitive to treatment effects, HAM-D17,
MADRS, CGI-S and CGI-I scores present a consistent picture of response to venlafaxine treatment.
Background
Many instruments have been developed to measure out-
comes in studies of patients with major depressive disor-
der (MDD). Among them, the Hamilton Depression
Rating Scale (HAM-D) [1], the Montgomery sberg Depres-
sion Rating Scale (MADRS) [2], and the Clinical Global
Impressions-Severity scale (CGI-S) and -Improvement
scale (CGI-I) [3], are investigator-rated instruments; the
CGI-I differs from the other three scales in that it assesses
the degree of symptom improvement rather than absolute
severity of symptoms or specific pathology [3]. The HAM-
D and the MADRS scales measure depressive symptoms,
whereas the CGI-S and CGI-I assess global outcome.
The HAM-D was developed in the 1950s to evaluate effi-
cacy of first-generation antidepressants; the 17-item
HAM-D (HAM-D17) has been accepted by many as the
standard for measuring therapeutic efficacy in clinical tri-
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als [1]. However, one problem with the HAM-D is that
individual items are often multidimensional, with poor
inter-rater and retest reliability. As a result, the HAM-D
total score can be ambiguous [4]. The MADRS was
designed to address some of the limitations of the HAM-
D. Specifically, the MADRS may be more sensitive to treat-
ment-related changes in depression and may better distin-
guish responders from non-responders [2,5]. Recent
analyses have confirmed the correlation between HAM-D,
MADRS, and CGI-S in a systematic literature review and
two retrospective chart reviews [4-6].
The present analysis was undertaken in a large dataset of
22 double-blind, placebo-controlled, clinical studies of
venlafaxine in patients with MDD to identify and assess
correlations among these 4 widely-used, rating scales: the
HAM-D17, MADRS, CGI-S, and CGI-I.
Methods
Studies and patients
Data were pooled from 22 multicenter, double-blind, pla-
cebo-controlled studies of venlafaxine (Table 1). All stud-
ies included adult patients with MDD, defined according
to the diagnostic criteria from the Diagnostic and Statistical
Manual of Mental Disorders (DSM-III [7], DSM-III-R [8], or
DSM-IV [9] depending on when the study was designed).
Outpatients were enrolled in 19 studies [10-22] and inpa-
tients were enrolled in the other 3 studies [23] [Wyeth
Research: Data on File. Collegeville, PA, USA: Wyeth
Research; 2006. unpublished data]. Two studies (016 and
206) enrolled patients with melancholia [10,23], and one
study (360) enrolled patients with concomitant anxi-
ety[21]. Study durations ranged from 4 weeks to 52 weeks.
Only data from patients receiving venlafaxine or placebo
were included in this analysis, although 15 studies
included an additional active-comparator arm [10-13,16-
18,21] [unpublished data]. Venlafaxine extended release
(ER) was used in 7 studies and venlafaxine immediate
release (IR) in 14. In one trial, both formulations were
used [14]. Venlafaxine IR was administered twice or three
times daily in fixed or flexible doses ranging from 25 to
375 mg/d [11-14,16-20] [unpublished data]. Venlafaxine
ER was administered once daily in fixed or flexible doses
ranging from 37.5 to 375 mg/d [13-15,21,22] [unpub-
lished data].
Statistical analysis
Continuous outcomes were defined as total change from
baseline for MADRS and HAM-D17, change in score from
baseline for CGI-S, and end point scores for CGI-I. These
scores were calculated using observed data for the total
patient populations at weeks 1, 2, 3, 4, 6, and 8 (for stud-
ies less than 8 weeks in duration, data were included for
the number of weeks available), and for the final on-ther-
apy (FOT) visit. HAM-D17, MADRS, CGI-S, and CGI-I
Table 1: Summary of 22 placebo-controlled clinical trials of venlafaxine for treatment of major depressive disordera
Study no. IR/ER Fixed/flexible
Dosing
Dose range (mg/day) Practice setting Duration (weeks) Median baseline HAM-D17
014 [11] IR Fixed 75, 150, 225 Outpatient 6 21
015 [12] IR Fixed 75, 150, 225 Outpatient 8 21
016 [10] IR Flexible 37.5 to 375 Inpatient 6 26
203 [16] IR Fixed ranges 75, 150 to 225, 300 to 375 Outpatient 6 22
206 [23] IR Flexible 150 to 375 Inpatient 4 27
208 [14] IR and ER Flexible IR: 75 to 150; ER: 75 to 150 Outpatient 12 22
209 [15] ER Flexible 75 to 225 Outpatient 8 21
211 [13] ER Flexible 75 to 225 Outpatient 8 22.5
300 IR Flexible 150 to 375 Inpatient 6 29
301 IR Flexible 75 to 225 Outpatient 6 22
302 [17] IR Flexible 75 to 200 Outpatient 6 22
303 [18] IR Flexible 75 to 225 Outpatient 6 22
313 [19] IR Fixed ranges 25, 50 to 75, 150 to 200 Outpatient 6 23
341 IR Flexible 100 to 200 Outpatient 52 22
342 [20] IR Fixed 75, 150, 200 Outpatient 12 22
343 IR Fixed ranges 100 to 150, 175 to 225 Outpatient 14 20
360 [21] ER Flexible 75 to 225 Outpatient 12 25
367 [22] ER Fixed 75, 150 Outpatient 8 25
372 IR Flexible 200 to 375 Outpatient 6 22
384 ER Flexible 150 to 375 Outpatient 6 25
402 ER Flexible 37.5 to 300 Outpatient 10 23
414 ER Flexible 37.5 to 300 Outpatient 10 22
ER, extended release; HAM-D17, 17-item Hamilton Depression Rating Scale; IR, immediate release.
aData on File at Wyeth Research. 2006.Annals of General Psychiatry 2009, 8:4 http://www.annals-general-psychiatry.com/content/8/1/4
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scores were stratified by treatment arm, and Pearson cor-
relation coefficients were calculated for all possible pairs
of the four scales (HAM-D17 vs MADRS, HAM-D vs CGI-S,
HAM-D17 vs CGI-I, MADRS vs CGI-S, MADRS vs CGI-I,
CGI-S vs CGI-I) for each of the data points.
The four scales also were used to determine binary out-
comes (response or no response). For CGI-I and CGI-S,
response was defined as scores ≤2, and for HAM-D17 and
MADRS total scores, response was defined as a 50% or
greater decrease from baseline. Pearson correlation coeffi-
cients were determined for all possible pairs of the four
scales for binary outcomes at weeks 1 through 8. Correla-
tions were calculated for the FOT scores for the total pop-
ulation, and separately for those in the venlafaxine and
placebo arms.
Pearson product-moment correlation coefficient (r), a
measure of the tendency of two variables to increase or
decrease together, was used to measure the correlation of
a pair of two efficacy variables measured on the same sub-
ject. Effect sizes (Cohen d) were calculated to measure the
magnitude of the treatment effect at the FOT evaluation
for the pooled data and individually for each study.
Results
At baseline, 5,117 observations were available for the
HAM-D17, 4,871 for the MADRS, and 5,103 for the CGI-S,
respectively. Mean baseline scores were 23.0, 29.1, and
4.4 for HAM-D17, MADRS, and CGI-S, respectively. Pre-
treatment correlations were 0.52 (CGI-S and HAM-D17),
0.53 (CGI-S and MADRS), and 0.62 (HAM-D17  and
MADRS).
Correlations between scales were significant at all time
points (p < 0.0001) and increased over the course of treat-
ment. At week 8, correlations ranged from 0.82 (CGI-S
and CGI-I) to 0.92 (HAM-D17 and MADRS) (Figure 1).
Correlations for the FOT scores also were significant (p <
0.0001), ranging from 0.87 (CGI-S and CGI-I) to 0.93
(HAM-D17 and MADRS) (Figure 2). Comparisons were
Correlation coefficients, changes from baseline (all patients) Figure 1
Correlation coefficients, changes from baseline (all patients). CGI-I, Clinical Global Impressions Improvement scale; 
CGI-S, Clinical Global Impressions Severity scale; HAM-D17, 17-item Hamilton Rating Scale for Depression; MADRS, Mont-
gomery sberg Depression Rating Scale.Annals of General Psychiatry 2009, 8:4 http://www.annals-general-psychiatry.com/content/8/1/4
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statistically similar for the total population, the venlafax-
ine group, and the placebo group.
Correlation coefficients between binary outcomes (that is,
response) were lower, ranging from 0.42 (CGI-I and CGI-
S) to 0.61 (HAM-D17 and MADRS) at week 1 and from
0.61 (CGI-I and CGI-S) to 0.81 (HAM-D17 and MADRS) at
week 8 (Figure 3). The correlations between binary out-
comes at the FOT visit ranged from 0.68 (CGI-I and CGI-
S) to 0.82 (MADRS and HAM-D17) (Figure 4). All correla-
tion coefficients were significant at all data points (p <
0.0001).
Pooled effect sizes for the continuous outcomes ranged
from 0.39 on the CGI-I to 0.42 on the CGI-S (Figure 5).
Effect sizes for the binary outcomes were lower, ranging
from 0.31 (CGI-I response) to 0.41 (CGI-S response).
Although differences were small, MADRS and CGI-I were
better able to detect differences between venlafaxine and
placebo than HAM-D17 or CGI-S for both sets of out-
comes. Effect sizes across the individual studies varied
considerably, but the pattern of results was largely consist-
ent with that of the pooled data. In the majority of studies,
Pearson correlation coefficient, changes from baseline (final  on therapy) Figure 2
Pearson correlation coefficient, changes from base-
line (final on therapy). CGI-I, Clinical Global Impressions 
Improvement scale; CGI-S, Clinical Global Impressions 
Severity scale; HAM-D17, 17-item Hamilton Rating Scale for 
Depression; MADRS, Montgomery sberg Depression Rating 
Scale.
Correlation between definitions of response (all patients) Figure 3
Correlation between definitions of response (all patients). CGI-I, Clinical Global Impressions Improvement scale; CGI-
S, Clinical Global Impressions Severity scale; HAM-D17, 17-item Hamilton Rating Scale for Depression; MADRS, Montgomery 
sberg Depression Rating Scale.Annals of General Psychiatry 2009, 8:4 http://www.annals-general-psychiatry.com/content/8/1/4
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effect sizes were greater on the CGI-I than CGI-S (contin-
uous outcomes: 12 of 22 studies; response: 15 of 22 stud-
ies) and were greater on the MADRS compared with the
HAM-D (continuous: 12 of 21 studies; response: 14 of 21
studies) (data not shown).
Discussion
The data presented here, which are derived from a large
pooled dataset from 22 clinical trials, confirm and expand
results of earlier comparisons of these 4 commonly used
depression rating scales [4-6]. Previous analyses have
included data from samples that were smaller and rather
homogeneous in terms of baseline depression severity
and duration of treatment; these analyses evaluated treat-
ment effects with a variety of antidepressants, including
tricyclic antidepressants, selective serotonin reuptake
inhibitors, and serotonin-norepinephrine reuptake inhib-
itors [5,6]. The trials in this analysis all included patients
with MDD. However, the diagnostic criteria differed
according to the DSM criteria accepted at the time individ-
ual studies were designed. All studies in this analysis used
venlafaxine; however, they differed in the venlafaxine for-
mulation used, dosing regimens (fixed or flexible), and
duration of study treatment. The variability among the
studies analysed here did not appear to confound the
results, as the observations made using the HAM-D17,
MADRS, CGI-S, and CGI-I were highly correlated. Further-
more, despite the differences between this and other anal-
yses, the findings are consistent [6]. As might be expected,
the highest correlations were between the HAM-D17 and
the MADRS rating scales, which share several items, have
similar modes of administration and rating, and are gen-
erally performed by the same clinician. However, in some
clinical trials, depression rating assessments and assess-
ments of global illness severity or improvement may be
performed by different clinicians; this may have contrib-
uted to the lower correlations between the HAM-D17 or
MADRS scales and the CGI scales observed in this analy-
sis. The consistently and modestly lower correlations
between the CGI-S and CGI-I scales were unexpected as
these scales are sometimes considered interchangeable.
However, this may be explained by the relatively narrow
distribution of the score range (1 to 7) compared with the
ranges for the HAM-D17 and MADRS total scores.
Although they were significant, correlation coefficients
among binary outcomes based on the scales were lower
than those for the change from baseline or FOT scores.
Moreover, effect sizes were smaller for all scales in meas-
uring the binary outcomes. These differences may be
related to the definitions of response or no response that
were used for the different scales. Some patients may have
experienced significant improvement, which would be
reflected in the change from baseline, although the scores
did not meet the threshold for response.
Conclusion
Overall, these results suggest that HAM-D17, MADRS,
CGI-S, and CGI-I scores present a consistent picture of
response to antidepressant therapy with venlafaxine.
Correlation between definitions of response (final on ther- apy) Figure 4
Correlation between definitions of response (final on 
therapy). CGI-I, Clinical Global Impressions Improvement 
scale; CGI-S, Clinical Global Impressions Severity scale; 
HAM-D17, 17-item Hamilton Rating Scale for Depression; 
MADRS, Montgomery sberg Depression Rating Scale.
Effect size for venlafaxine vs placebo (all patients, final on  therapy) Figure 5
Effect size for venlafaxine vs placebo (all patients, 
final on therapy). CGI-I, Clinical Global Impressions 
Improvement scale; CGI-S, Clinical Global Impressions 
Severity scale; HAM-D17, 17-item Hamilton Rating Scale for 
Depression; MADRS, Montgomery sberg Depression Rating 
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